Core Viewpoint - Guoen Technology (02768.HK) plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, aiming for a price range of HKD 34.00 to 42.00 per share, with trading expected to commence on February 4, 2026 [2][3] Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [3] - The company operates in two main sectors: the large chemical sector, providing solutions to manufacturers in automotive, new energy, and home appliances, and the health sector, supplying raw materials for supplements and pharmaceuticals [3][4] Market Position - In the large chemical industry, Guoen is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, holding a market share of 2.5% as of 2024 [4] - Guoen is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Financial Performance - The company has shown strong revenue growth, with revenues of RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate (CAGR) of 19.6% from 2022 to 2024 [7] - The sales figures for the fiscal years 2023 and 2024 indicate year-on-year growth rates of 30.1% and 10.0%, respectively [7] Market Trends - The market for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion by 2024, with a CAGR of 15.7% [8] - The market is expected to continue strong growth, reaching RMB 1,037.5 billion by 2029, with a forecasted CAGR of 14.1% from 2025 to 2029 [8] Use of Proceeds - The net proceeds from the share offering are estimated at approximately HKD 1.057 billion, with plans to allocate 50% for establishing a new production base in Thailand, 35% for expanding capacity in Yixing, and 10% for investments in Hong Kong [9]

Company Overview - Guoen Co., Ltd. (002768) is undergoing a listing hearing on the Hong Kong Stock Exchange, sponsored exclusively by China Merchants Securities International. The company operates in two main segments: Advanced Chemicals (Chemical New Materials) and Health Products (Gelatin, Collagen, and related upstream and downstream products) [1] Advanced Chemicals Segment - The Advanced Chemicals segment focuses on the chemical new materials industry, offering products such as green petrochemical materials (e.g., aromatic olefins, styrene, polystyrene) and organic polymer modified materials and composites. These products serve downstream industries including automotive, new energy, and home appliances [1] - According to Frost & Sullivan, Guoen Co., Ltd. is the second largest company in China for organic polymer modified materials and organic polymer composites by sales revenue in 2024, holding a market share of 2.5%. It is also the largest producer of polystyrene in China by production capacity in 2024 [1] Health Products Segment - The Health Products segment focuses on the natural collagen industry, developing collagen peptide derivatives and end products through its subsidiary Dongbao Biological (300239). The primary customers are medical and pharmaceutical manufacturers [1] - Based on Frost & Sullivan's data, Guoen Co., Ltd. ranks as the second largest producer of bone gelatin in China by production volume in 2024, and it is the largest domestic brand in this category. Additionally, it is the second largest domestic brand in the hollow capsule production sector in China, according to 2024 production volume estimates [1] Market Outlook - The market for organic polymer modified materials and organic polymer composites in China is projected to grow from RMB 544.8 billion in 2024 to RMB 1,037.5 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.1% [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies, including Guoen Technology, regarding their overseas listing applications [1] - Guoen Technology submitted its listing application to the Hong Kong Stock Exchange on June 26, 2025, with CMB International as its sole sponsor [1] - The CSRC has requested Guoen Technology to clarify the debt repayment ability of its actual controller and whether its projects are classified as "high energy consumption" or "high emissions" [1] Group 2 - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency [3] - The company implements a "one body, two wings" development strategy, establishing a vertically integrated industrial platform in the large chemical and health industries [3] - In the large chemical sector, Guoen Technology is involved in the chemical new materials industry chain, creating a "new materials+" industrial ecosystem [3] - The company extends its operations upstream to green petrochemical materials and deepens its downstream layout in various industries, including electronics, automotive, new energy, and energy storage [3] - In the health sector, Guoen Technology focuses on the natural collagen industry, developing a vertically integrated product layout from animal collagen to end products [3]

Core Insights - Dongbao Biological achieved operating revenue of 369 million yuan and a net profit attributable to shareholders of 36.97 million yuan in the first half of 2025 [1] - The company focuses on the natural collagen sector and implements a health development strategy amid uncertainties in the external environment, particularly in the gelatin market [1][2] - Dongbao Biological is actively responding to market challenges through product segmentation, exploring new application fields, and enhancing digital transformation [1][2] Financial Performance - In the first half of 2025, Dongbao Biological's revenue was 369 million yuan, with a net profit of 36.97 million yuan [1] - The company faced short-term declines in sales and prices due to fluctuations in the gelatin market [1] Strategic Initiatives - Dongbao Biological is enhancing its research and development system, focusing on demand-driven innovation and application breakthroughs [2] - The company is advancing various projects, including specialized collagen for cashmere textiles and low-endotoxin gelatin, which are in the process of market engagement [2] - The company is also pushing for the industrialization of hair care collagen products and expanding its product matrix into multiple application fields [2][3] Market Positioning - Dongbao Biological is committed to developing high-value-added collagen derivatives, maintaining its leading position in the natural collagen industry [3] - The company aims to evolve into a comprehensive enterprise group in the health industry, focusing on medical, beauty, health, and food sectors [3]

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its capital market strategy and aiming to enhance its international influence and competitiveness [1] Group 1: Company Overview - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency and implementing a "one body, two wings" development strategy in the large chemical and health industries [2] - In the large chemical sector, Guoen Technology is the second-largest organic polymer material modification producer in China and the largest producer of polystyrene, showcasing its strong market position [2] - In the health industry, Guoen Technology's subsidiary Dongbao Biological has established a comprehensive product layout from collagen to "collagen +", becoming a significant player in the health sector [3] Group 2: Financial Performance - The company has shown strong revenue growth, with total revenues of approximately RMB 134.06 billion, RMB 174.39 billion, and RMB 191.88 billion for the fiscal years 2022, 2023, and 2024, respectively [4] - The main revenue source is the large chemical sector, contributing RMB 183.3 billion in 2024, accounting for 95.6% of total revenue, while the health sector contributed RMB 8.53 billion, representing 4.4% of total revenue [5] - The overall gross profit margins for the fiscal years 2022, 2023, and 2024 were 11.8%, 9.2%, and 8.3%, respectively, with the health sector showing a higher margin of 23.2% in 2024 [6] Group 3: Future Prospects - The successful listing on the Hong Kong Stock Exchange is expected to provide new development opportunities for the company, allowing it to expand capacity, increase R&D investment, and enhance its domestic and international market presence [6] - The company's strong foundation in the large chemical and health sectors, along with its financial performance and future growth potential, positions it as a noteworthy investment opportunity [7]

Core Viewpoint - Guoen Technology is a comprehensive enterprise group driven by technological innovation, focusing on long-term scale efficiency and implementing a "one body, two wings" development strategy in the large chemical and health industries [2]. Group 1: Industry Overview - In the large chemical industry, Guoen Technology is deeply engaged in the chemical new materials industry chain, building a "new materials+" ecosystem and enhancing its vertical integration layout [2]. - The company is the second-largest organic polymer material modification producer in China by revenue in 2024 and the largest producer of polystyrene by capacity [2]. - In the health industry, Guoen Technology focuses on the natural collagen industry, establishing a vertically integrated product layout from animal collagen to end products [2][3]. Group 2: Financial Performance - For the fiscal years 2022, 2023, and 2024, Guoen Technology reported total revenues of approximately RMB 13.406 billion, RMB 17.438 billion, and RMB 19.188 billion respectively [3][5]. - The net profit for the same periods was approximately RMB 724 million, RMB 540 million, and RMB 721 million respectively [3][5]. - The gross profit figures for the fiscal years were RMB 1.580 billion, RMB 1.601 billion, and RMB 1.592 billion respectively, indicating a stable gross profit margin [5].